Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1
Jeffrey L. Lennox(Emory University), Susan L. Koletar(Johns Hopkins University), Randi Y. Leavitt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lumine H. Na(Brigham and Women's Hospital), Heather J. Ribaudo(Harvard University), Carl J. Fichtenbaum(Cancer Research And Biostatistics), David W. Haas(The Coordinating Center), Catherine Godfrey(Brigham and Women's Hospital), Daniel Seekins(Brigham and Women's Hospital), Manish Sagar(Evidence (Italy)), Rachel M. Presti(Johns Hopkins University), Raphael J. Landovitz(APLA Health), Susan E. Cohn(Brigham and Women's Hospital), James F. Rooney(Gilead Sciences (United States)), Daniel R. Kuritzkes(Brigham and Women's Hospital), Bryan Baugh(Brigham and Women's Hospital), Francesca Aweeka(University of California, San Francisco), Todd T. Brown(Johns Hopkins University), Ighovwerha Ofotokun(Emory University), Constance A. Benson(University of Colorado Health), Judith S. Currier, Grace A. McComsey(Johns Hopkins University), Kristine B. Patterson(University of North Carolina at Chapel Hill)
Cited by 260
Related Papers
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
|New England Journal of Medicine|2009|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|978
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|847